SCHEMBL23218256

SCHEMBL23218256

N#Cc1cc(Br)cc(OCc2cccnc2)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.50
CYP11B2 P19099 1/20 0.47
MAOB P27338 2/20 0.43
MAPK1 P28482 3/20 0.43
LRRK2 Q5S007 1/20 0.43
ALK Q9UM73 1/20 0.42
ADAM17 P78536 2/20 0.42
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
CYP19A1 P11511 1/20 0.40
GPR132 Q9UNW8 1/20 0.40
IKBKB O14920 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29593169 1.00 CYP11B1 (0.50) CYP11B1CYP11B2MAOBMAPK1LRRK2
SCHEMBL22489859 0.83 MAOB (0.63) MAOBGAAMAPT
SCHEMBL18002080 0.81 CYP11B1 (0.48) CYP11B1CYP11B2MAOBMAPK1ALK
SCHEMBL4060132 0.78 MAPK1 (0.56) CYP11B1CYP11B2MAPK1ALDH1A1HTT
SCHEMBL28048524 0.76 MAPK1 (0.64) CYP11B1CYP11B2MAPK1ALDH1A1HTT
SCHEMBL28011530 0.75 MAPK1 (0.64) MAOBMAPK1GPR132
SCHEMBL200551 0.74 MAOB (0.52) MAOBCYP19A1
SCHEMBL4937139 0.74 CYP11B1 (0.47) CYP11B1CYP11B2MAPK1ALKHSD17B10
SCHEMBL23219060 0.74 LRRK2 (0.50) MAOBLRRK2HSD17B10ALDH1A1CYP19A1
SCHEMBL29591341 0.74 LRRK2 (0.50) MAOBLRRK2HSD17B10ALDH1A1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CYP11B1 1811/4885CYP11B2 1368/4885MAOB 1035/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CYP11B1 1854/4885CYP11B2 1922/4885MAOB 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.